Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Total Non-Current Liabilities (2024 - 2025)

Rein Therapeutics (RNTX) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $7.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.5 million, a N/A change, with the full-year FY2024 number at $7.5 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $7.5 million for Q3 2025 at Rein Therapeutics, down from $9.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $9.5 million in Q2 2025 to a low of $7.5 million in Q3 2025.